Administrator | September 25, 2016

Yostra Labs

Yostra Labs

Affordable screening and diagnostics for diabetes.

Incubated since December 2016 Headquarters Bengaluru India Sector Health
Sub-sector Diabetes screening and treament Portfolio manager Aditya Jahagirdar

“We are a motivated interdisciplinary team of clinicians, designers and engineers, brought together by the common goal of making a positive impact in affordable healthcare.”
- Vinayak Nandalike, co-founder, Yostra Labs

The Entrepreneur

Vinayak Nandalike is the CEO and Founder. He is an entrepreneur with over 14 years of experience in management consulting and program management. He holds an MBA degree from The Indian School of Business.

Dr. Maruthy K.N is the Chief Scientific Advisor, and the Co-Founder. A physiology professor with over 20 years of experience, Dr. Maruthy has been pioneering innovations in bio-medical engineering. He holds a MD (Physiology) from Rajiv Gandhi University of Health Sciences.

The Challenge

India has approximately 69 million diabetic patients. About 30% of diabetics develop diabetic peripheral neuropathy and half of those will develop foot ulcers due to their condition. The poor are significantly at risk because of inadequate management of their condition. There is a critical need for affordable diagnostic devices to enable mass screening of diabetic patients for peripheral neuropathy, as well as a need for affordable treatment options for diabetic foot ulcers.

The Innovation

Conventional Diabetic Peripheral Neuropathy screening devices available in the market are bulky, not portable, expensive, and need trained healthcare workers to operate the device.
The ‘Sparsh’ diagnostic device treats diabetic peripheral neuropathy (permanent damage to nerves in the feet, owing to diabetes). ‘Kadam’, another device, is significantly cost-effective and accessible in comparison with other treatment methods and can be operated with minimum resources.

The Impact

Both ‘Sparsh’ and ‘Kadam’ have far reaching social impact providing greater healthcare access to BoP diabetic patients. Sparsh will enable early diagnosis of DPN thus helping patients to manage it better and avoid complications. Kadam can potentially prevent 2 lakh amputations per year in India.

[do_widget id=text-7]